The ACT Canada Consortium consists of hundreds of investigators, stakeholders, and highly qualified research personnel from 11 trial units and 28 research networks across Canada. The central guiding principle of the ACT Consortium is that its activities will accelerate, optimize, and facilitate the conduct, implementation, and results translation from high-quality, high-impact randomized controlled trials (RCTs) to improve health in Canada and around the world.
CANet is one of the many networks that is supported by ACT which allows CANet Network Investigators to apply for research monies and in-kind support for clinical trials.
ACT is providing research personnel to our Network to improve our infrastructure support and further our Network activities. Examples of in-kind support include insurance for clinical trials, assistance with identification and activation of research centres internationally, amongst others.
To learn more about ACT, visit www.act-aec.ca.
DEADLINE EXTENDED
ACT has recently announced the first Call for Proposals: Supporting the Completion of High-Impact Randomized Controlled Trials.
A total of $2 million dollars is available for this competition. The maximum funding per application is $200,000.
CANet will only be allowed to support 3 submissions in this competition.
If you intend to apply, you must send your full application to CANet by Friday, March 24, 2023 (11:59 PM Pacific Time) to Kevin O’Neil at [email protected].
Those selected to proceed to the full application will be provided with a letter of support from CANet before ACT’s deadline of April 3, 2023.
The First Annual ACT Canada Consortium Meeting will be held at the Hamilton Convention Centre in Hamilton, ON, on April 17th-18th, 2023.
This meeting will spotlight presentations on Canadian Biotechnology and include themed breakout sessions aimed at furthering Canadian research partnerships between Canadian Biotechnology companies and Canadian Clinical Trialists.
Please contact Dr. Ratika Parkash at [email protected] if you are interested in learning more about this initiative or if you would like to attend the meeting.